Cargando…

Enhancer RNA promotes resistance to radiotherapy in bone-metastatic prostate cancer by m(6)A modification

Rationale: Prostate cancer metastasizes to the bone with the highest frequency and exhibits high resistance to (177)Lu-prostate-specific membrane antigen (PSMA) radioligand therapy. Little is known about bone metastatic prostate cancer (mPCa) resistance to radiation. Methods: We filtered the metasta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yu, Wen, Simeng, Li, Hang, Pan, Chun-Wu, Wei, Yulei, Huang, Ting, Li, Zhaochen, Yang, Yinhui, Fan, Saijun, Zhang, Yingyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830431/ https://www.ncbi.nlm.nih.gov/pubmed/36632223 http://dx.doi.org/10.7150/thno.78687

Ejemplares similares

Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine
por: Wen, Simeng, et al.
Publicado: (2020)

Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer
por: Inaba, Koji, et al.
Publicado: (2021)

Six‐transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial–mesenchymal
por: Wei, Haotian, et al.
Publicado: (2023)

Functional roles of antisense enhancer RNA for promoting prostate cancer progression
por: Pan, Chun-Wu, et al.
Publicado: (2021)

The essential roles of m(6)A modification in osteogenesis and common bone diseases
por: Gu, Yuxi, et al.
Publicado: (2023)

Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy
por: Denis-Bacelar, Ana M, et al.
Publicado: (2018)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

The emerging roles of m(6)A modification in liver carcinogenesis
por: Pan, Xue-yin, et al.
Publicado: (2021)

The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”
por: Ali, Adnan, et al.
Publicado: (2020)

m(6)A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2‐mediated IGF1R mRNA stabilization
por: Lang, Chuandong, et al.
Publicado: (2021)

IGF2BP3 promotes adult myocardial regeneration by stabilizing MMP3 mRNA through interaction with m6A modification
por: Li, Simeng, et al.
Publicado: (2023)

Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation
por: Kalaitzis, Christos, et al.
Publicado: (2014)

The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy
por: Shriwas, Omprakash, et al.
Publicado: (2021)

Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response
por: Klusa, Daria, et al.
Publicado: (2021)

Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer
por: Ollivier, Luc, et al.
Publicado: (2021)

Clinical outcome in metastatic prostate cancer after primary radiotherapy
por: Moll, Matthias, et al.
Publicado: (2022)

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Ali, Adnan, et al.
Publicado: (2021)

Immunomodulatory effects of carbon ion radiotherapy in patients with localized prostate cancer
por: Hu, Wei, et al.
Publicado: (2022)

Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy
por: Ayoub, Heba Maged, et al.
Publicado: (2023)

Role of Hakai in m(6)A modification pathway in Drosophila
por: Wang, Yanhua, et al.
Publicado: (2021)

Osteoimmunomodulatory effects of biomaterial modification strategies on macrophage polarization and bone regeneration
por: Xie, Yajuan, et al.
Publicado: (2020)

Matrices and Affinity Ligands for Antibody Purification and Corresponding Applications in Radiotherapy
por: Xue, Aiying, et al.
Publicado: (2022)

Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis
por: Li, Dongyang, et al.
Publicado: (2017)

Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models
por: Gupta, Nisha, et al.
Publicado: (2023)

Carbon Ion Radiotherapy Evokes a Metabolic Reprogramming and Individualized Response in Prostate Cancer
por: Ning, Renli, et al.
Publicado: (2021)

Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas
por: Yang, Yongqiang, et al.
Publicado: (2021)

Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
por: Tabata, Ken-ichi, et al.
Publicado: (2012)

Link Between m6A Modification and Cancers
por: Liu, Zhen-Xian, et al.
Publicado: (2018)

Animal models of bone metastatic prostate cancer
por: Tae, Jong Hyun, et al.
Publicado: (2023)

N(6)‐methyladenosine (m(6)A) RNA modification in human cancer
por: Huo, Fu‐Chun, et al.
Publicado: (2020)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?
por: Bišof, Vesna
Publicado: (2019)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT
por: Karagiannis, Vasileios, et al.
Publicado: (2022)

The Role of m(6)A Modification and m(6)A Regulators in Esophageal Cancer
por: Li, Yuekao, et al.
Publicado: (2022)

Dynamic regulation and functions of mRNA m6A modification
por: Wang, Shanshan, et al.
Publicado: (2022)

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
por: Wu, Changping, et al.
Publicado: (2015)

m6A modifications regulate intestinal immunity and rotavirus infection
por: Wang, Anmin, et al.
Publicado: (2022)

The role of m(6)A modification in physiology and disease
por: Yang, Chuan, et al.
Publicado: (2020)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
por: Burdett, Sarah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pooifehk1dm38429h88nla280n